NightHawk Biosciences’ stock is owned by many different retail and institutional investors. Top institutional investors include Simplex Trading LLC (0.00%). Insiders that own company stock include Edward B Smith III and John K A Prendergast. Sign-up to receive the latest news and ratings for NightHawk Biosciences and its competitors with MarketBeat’s FREE daily newsletter. Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index quotes are real-time.
- They rarely distribute dividends to shareholders, opting for reinvestment in their businesses.
- NightHawk Biosciences shares reverse split before market open on Friday, December 11th 2020.
- The Zacks Industry Rank assigns a rating to each of the 265 X Industries based on their average Zacks Rank.
- We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view.
In the Morningstar Style Box, large-cap names account for the largest 70% of U.S. stocks, mid-cap names account for the largest 70–90%, and small-cap names are the remaining 10% of companies. Market cap, also known as market capitalization, is the total market value of a company. It’s calculated by multiplying the current market price by the total number of shares outstanding. 1 Wall Street analysts have issued “buy,” “hold,” and “sell” ratings for NightHawk Biosciences in the last twelve months.
Carol Massar and Tim Stenovec host a look back at the best interviews, discussions and more. Upgrade to MarketBeat All Access to add more stocks to your watchlist. NightHawk Biosciences trades on the New York Stock Exchange under the ticker symbol “NHWK.”
STOCKS EXTEND GAINS AMID TECH EARNINGS, BANKING DRAMA
A valuation method that multiplies the price of a company’s stock by the total number of outstanding shares. Shares Sold ShortThe total number of shares of a security that have been sold short and not yet repurchased.Change from LastPercentage change in short interest from the previous report to the most recent report. Exchanges report short interest twice a month.Percent of FloatTotal short positions relative to the number of shares available to trade. NEW YORK — Visicu Inc. vaulted as much as 62% in its stock market debut Wednesday as investors bid up shares of the company whose technology helps hospitals monitor intensive-care patients. © 2023 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided ‘as-is’ and solely for informational purposes, not for trading purposes or advice, and is delayed.
The company has a collaboration with Dr. James Shapiro at University of Alberta to manufacture surrogate mouse version of PTX-35. The company was formerly known as Heat Biologics, Inc. and changed its name to NightHawk Biosciences, Inc. in May 2022. NightHawk Biosciences, Inc. was incorporated in 2008 and is headquartered in Morrisville, North Carolina. At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors.
NHWK Company Calendar
Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares.
52 week high is the highest price of a stock in the past 52 weeks, or one year. NightHawk Biosciences Inc 52 week high is $3.42 as of April 28, 2023. One share of NHWK stock can currently be purchased for approximately $0.66.
Market Cap is calculated by multiplying the number of shares outstanding by the stock’s price. To calculate, start with total shares outstanding and subtract the number of restricted shares. Restricted stock typically is that issued to company insiders with limits on when it may be traded.Dividend YieldA company’s dividend expressed as a percentage of its current stock price. NightHawk Biosciences, Inc., an integrated biopharmaceutical company, engages in the development of immune therapies and vaccines. The company’s therapies are used to modulate the immune system against various diseases, including cancer and infectious diseases. The company develops HS-110, which has completed enrollment in a Phase II clinical trial to treat patients with advanced non-small cell lung cancer; and HS-130 that is in Phase I clinical trial for the treatment of advanced solid tumors.
Morningstar Quantitative ratings for equities are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Data are provided ‘as is’ for informational purposes only and are not intended for trading purposes. Data may be intentionally delayed pursuant to supplier requirements. News Corp is a global, diversified media and information services company focused on creating and distributing authoritative and engaging content and other products and services. The technique has proven to be very useful for finding positive surprises. In fact, when combining a Zacks Rank #3 or better and a positive Earnings ESP, stocks produced a positive surprise 70% of the time, while they also saw 28.3% annual returns on average, according to our 10 year backtest.
NEW YORK – Visicu on Tuesday increased the price of its initial public offering as Wall Street cast a favoring eye on one of the smaller deals on the calendar. CINCINNATI — Despite last week’s thin trading conditions, the U.S. markets weren’t lacking for technical developments. NightHawk Biosciences’ stock was trading at $0.8051 at the beginning of the year. Since then, NHWK stock has decreased by 18.0% and is now trading at $0.66.
If you aren’t doing this a couple times a week, you need to start. Grab your salt and pour some directly down your drain at night. Bloomberg Businessweek Highlights from a week-long virtual event bringing Bloomberg Businessweek magazine to life.
This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.27% per year. These returns cover a period from January 1, 1988 through April 3, 2023.
Our calculations are based on comprehensive, delayed quotes. The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It’s calculated by dividing the current share price by the earnings per share .
NightHawk Biosciences Provides Third Quarter 2022 Business Update
A stock’s beta measures how closely tied its price movements have been to the performance of the overall market. Style is an investment factor that has a meaningful impact on investment risk and returns. Style is calculated by combining value and growth scores, which are first individually calculated. There may be delays, omissions, or inaccuracies in the Information. The scores are based on the trading styles of Value, Growth, and Momentum. There’s also a VGM Score (‘V’ for Value, ‘G’ for Growth and ‘M’ for Momentum), which combines the weighted average of the individual style scores into one score.
The idea is that more recent information is, generally speaking, more accurate and can be a better predictor of the future, which can give investors an advantage in earnings season. The Zacks Industry Rank assigns a rating to each of the 265 X Industries based on their average Zacks Rank. Sign Up NowGet this delivered to your inbox, and more info about our products and services. 52 week low is the lowest price of a stock in the past 52 weeks, or one year. NightHawk Biosciences Inc 52 week low is $0.66 as of April 28, 2023.
The formula for calculating https://1investing.in/ yield is to divide the annual dividend paid per share by the stock price. NightHawk Biosciences, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient’s T-cell mediated immune system against cancer. Its TCAP product candidates from the company’s ImPACT and ComPACT platforms are produced from allogeneic cell lines expressing tumor-specific proteins common among cancers. The company was founded by Jeffrey Alan Wolf on June 10, 2008 and is headquartered in Morrisville, NC.
We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive. Provide specific products and services to you, such as portfolio management or data aggregation. Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.
Real-time quotes, advanced visualizations, backtesting, and much more. Verify your identity, personalize the content you receive, or create and administer your account. We’d like to share more about how we work and what drives our day-to-day business. CompareNHWK’s historical performanceagainst its industry peers and the overall market. Zacks Earnings ESP looks to find companies that have recently seen positive earnings estimate revision activity.
Sell every Stock except ONE Markets are down…But Jeff Clark couldn’t care less because he ignores almost every stock in the market except ONE. He lives financially free trading this One Stock Once per month… Maintaining independence and editorial freedom is essential to our mission of empowering investor success.
It can also be 3 3 4 calculate and interpret variance and normal by dividing the company’s Market Cap by the Net Profit. We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management.